PMID- 19242411
OWN - NLM
STAT- MEDLINE
DCOM- 20090529
LR  - 20211020
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Print)
IS  - 0028-0836 (Linking)
VI  - 458
IP  - 7238
DP  - 2009 Apr 2
TI  - Adaptation of HIV-1 to human leukocyte antigen class I.
PG  - 641-5
LID - 10.1038/nature07746 [doi]
AB  - The rapid and extensive spread of the human immunodeficiency virus (HIV) epidemic 
      provides a rare opportunity to witness host-pathogen co-evolution involving 
      humans. A focal point is the interaction between genes encoding human leukocyte 
      antigen (HLA) and those encoding HIV proteins. HLA molecules present fragments 
      (epitopes) of HIV proteins on the surface of infected cells to enable immune 
      recognition and killing by CD8(+) T cells; particular HLA molecules, such as 
      HLA-B*57, HLA-B*27 and HLA-B*51, are more likely to mediate successful control of 
      HIV infection. Mutation within these epitopes can allow viral escape from CD8(+) 
      T-cell recognition. Here we analysed viral sequences and HLA alleles from >2,800 
      subjects, drawn from 9 distinct study cohorts spanning 5 continents. Initial 
      analysis of the HLA-B*51-restricted epitope, TAFTIPSI (reverse transcriptase 
      residues 128-135), showed a strong correlation between the frequency of the 
      escape mutation I135X and HLA-B*51 prevalence in the 9 study cohorts (P = 
      0.0001). Extending these analyses to incorporate other well-defined CD8(+) T-cell 
      epitopes, including those restricted by HLA-B*57 and HLA-B*27, showed that the 
      frequency of these epitope variants (n = 14) was consistently correlated with the 
      prevalence of the restricting HLA allele in the different cohorts (together, P < 
      0.0001), demonstrating strong evidence of HIV adaptation to HLA at a population 
      level. This process of viral adaptation may dismantle the well-established HLA 
      associations with control of HIV infection that are linked to the availability of 
      key epitopes, and highlights the challenge for a vaccine to keep pace with the 
      changing immunological landscape presented by HIV.
FAU - Kawashima, Yuka
AU  - Kawashima Y
AD  - Division of Viral Immunology, Center for AIDS Research, Kumamoto University, 
      2-2-1 Honjo, Kumamoto 860-0811, Japan.
FAU - Pfafferott, Katja
AU  - Pfafferott K
FAU - Frater, John
AU  - Frater J
FAU - Matthews, Philippa
AU  - Matthews P
FAU - Payne, Rebecca
AU  - Payne R
FAU - Addo, Marylyn
AU  - Addo M
FAU - Gatanaga, Hiroyuki
AU  - Gatanaga H
FAU - Fujiwara, Mamoru
AU  - Fujiwara M
FAU - Hachiya, Atsuko
AU  - Hachiya A
FAU - Koizumi, Hirokazu
AU  - Koizumi H
FAU - Kuse, Nozomi
AU  - Kuse N
FAU - Oka, Shinichi
AU  - Oka S
FAU - Duda, Anna
AU  - Duda A
FAU - Prendergast, Andrew
AU  - Prendergast A
FAU - Crawford, Hayley
AU  - Crawford H
FAU - Leslie, Alasdair
AU  - Leslie A
FAU - Brumme, Zabrina
AU  - Brumme Z
FAU - Brumme, Chanson
AU  - Brumme C
FAU - Allen, Todd
AU  - Allen T
FAU - Brander, Christian
AU  - Brander C
FAU - Kaslow, Richard
AU  - Kaslow R
FAU - Tang, James
AU  - Tang J
FAU - Hunter, Eric
AU  - Hunter E
FAU - Allen, Susan
AU  - Allen S
FAU - Mulenga, Joseph
AU  - Mulenga J
FAU - Branch, Songee
AU  - Branch S
FAU - Roach, Tim
AU  - Roach T
FAU - John, Mina
AU  - John M
FAU - Mallal, Simon
AU  - Mallal S
FAU - Ogwu, Anthony
AU  - Ogwu A
FAU - Shapiro, Roger
AU  - Shapiro R
FAU - Prado, Julia G
AU  - Prado JG
FAU - Fidler, Sarah
AU  - Fidler S
FAU - Weber, Jonathan
AU  - Weber J
FAU - Pybus, Oliver G
AU  - Pybus OG
FAU - Klenerman, Paul
AU  - Klenerman P
FAU - Ndung'u, Thumbi
AU  - Ndung'u T
FAU - Phillips, Rodney
AU  - Phillips R
FAU - Heckerman, David
AU  - Heckerman D
FAU - Harrigan, P Richard
AU  - Harrigan PR
FAU - Walker, Bruce D
AU  - Walker BD
FAU - Takiguchi, Masafumi
AU  - Takiguchi M
FAU - Goulder, Philip
AU  - Goulder P
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - G0500384/MRC_/Medical Research Council/United Kingdom
GR  - R01 AI046995-10/AI/NIAID NIH HHS/United States
GR  - R01AI64060/AI/NIAID NIH HHS/United States
GR  - 1 R01 AI067073/AI/NIAID NIH HHS/United States
GR  - G0501777/MRC_/Medical Research Council/United Kingdom
GR  - R01 AI064060-06A1/AI/NIAID NIH HHS/United States
GR  - P30 AI110527/AI/NIAID NIH HHS/United States
GR  - R01 AI046995/AI/NIAID NIH HHS/United States
GR  - R01 AI067073/AI/NIAID NIH HHS/United States
GR  - R01 AI064060/AI/NIAID NIH HHS/United States
GR  - R01AI46995/AI/NIAID NIH HHS/United States
GR  - R01 AI060460/AI/NIAID NIH HHS/United States
GR  - G108/626/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20090225
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HIV Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (gag Gene Products, Human Immunodeficiency Virus)
SB  - IM
MH  - Alleles
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cohort Studies
MH  - Epitopes, T-Lymphocyte/chemistry/genetics/immunology
MH  - HIV Antigens/chemistry/genetics/immunology
MH  - HIV-1/genetics/*immunology/physiology
MH  - HLA-B Antigens/genetics/*immunology
MH  - Humans
MH  - Internationality
MH  - Leukocytes/*immunology
MH  - Polymorphism, Genetic
MH  - gag Gene Products, Human Immunodeficiency Virus/chemistry/genetics/immunology
PMC - PMC3148020
MID - NIHMS307142
EDAT- 2009/02/27 09:00
MHDA- 2009/05/30 09:00
PMCR- 2011/08/01
CRDT- 2009/02/27 09:00
PHST- 2008/10/13 00:00 [received]
PHST- 2008/12/22 00:00 [accepted]
PHST- 2009/02/27 09:00 [entrez]
PHST- 2009/02/27 09:00 [pubmed]
PHST- 2009/05/30 09:00 [medline]
PHST- 2011/08/01 00:00 [pmc-release]
AID - nature07746 [pii]
AID - 10.1038/nature07746 [doi]
PST - ppublish
SO  - Nature. 2009 Apr 2;458(7238):641-5. doi: 10.1038/nature07746. Epub 2009 Feb 25.